Status:
COMPLETED
Use of Atosiban in in Vitro Fertilization (IVF) Treatment
Lead Sponsor:
The University of Hong Kong
Collaborating Sponsors:
Vietnam National University
Nanfang Hospital, Southern Medical University
Conditions:
Subfertility
Eligibility:
FEMALE
18-43 years
Phase:
PHASE4
Brief Summary
The hypothesis of this randomized double blind study is that the live birth rates are significantly higher after the use of atosiban prior to the embryo transfer in patients undergoing in vitro fertil...
Detailed Description
In-vitro fertilization-embryo transfer (IVF-ET) treatment involves multiple follicular development following ovarian stimulation, oocyte retrieval and ET after fertilization. Despite recent advances i...
Eligibility Criteria
Inclusion
- Age \< 43 years
- Normal uterine cavity shown on ultrasound scanning
Exclusion
- Age \>=43
- Three previous IVF cycles
- Use of donor oocytes
- Natural IVF or IVM cycles
- Abnormal uterine cavity on ultrasound scanning
- ET canceled because of absent fertilization or risk of ovarian hyperstimulation syndrome
- Blastocyst transfer
- Undergoing preimplantation genetic diagnosis
- Recruited in the same study before
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT01501214
Start Date
December 1 2011
End Date
December 1 2013
Last Update
January 7 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Reproductive Medical Center of Nanfang Hospital
Guangzhou, Guangdong, China, 510515
2
CGRH, School of Medicine
Ho Chi Minh City, Ho Chi Minh City, Vietnam